Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plitidepsin + Bortezomib + Dexamethasone in R/R MM
NCT02100657Phase 1Completed
- Sponsor
- PharmaMar
- Start
- Jun 2014
- Primary completion
- Jun 2018
- Modality
- Cyclic Peptides, Peptide-Drug Conjugates
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of plitidepsin in multiple myeloma (MM), sponsored by PharmaMar. Primary endpoints: Recommended Dose of Plitidepsin in Combination With Bortezomib and Dexamethasone, Recommended Dose of Bortezomib in Combination With Plitidepsin and Dexamethasone and 2 more. Started Jun 2014; status: completed.
02
Drugs
plitidepsin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02100657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02100657.